{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-051566","form_type":"8-K","ticker":"KYMR","cik":"0001815442","company_name":"Kymera Therapeutics, Inc.","filed_at":"2024-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.301945+00:00","generated_at":"2026-06-03T00:48:53.931527+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Kymera Therapeutics Q1 2024 net loss $48.6M; cash $745M; pipeline progresses","bullets":["Net loss $48.6M in Q1 2024 vs $40.9M in Q1 2023; collaboration revenue $10.3M.","Cash, cash equivalents and investments $745M as of March 31, 2024.","Cash runway extended into first half of 2027 following $301M equity offering.","KT-474 IRAK4 degrader Phase 2 trials in HS and AD ongoing; topline data H1 2025.","KT-621 STAT6 degrader Phase 1 start H2 2024; KT-294 TYK2 degrader Phase 1 start H1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-051566","json":"https://secwatch.observer/filing/0000950170-24-051566.json","markdown":"https://secwatch.observer/filing/0000950170-24-051566.md","text":"https://secwatch.observer/filing/0000950170-24-051566.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815442/000095017024051566/0000950170-24-051566-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815442/000095017024051566/kymr-20240502.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T00:48:53.931527+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5f8d3f3e4c1b95f889416ff935a9dbd798a70e04","claim":"Kymera Therapeutics, Inc. reported financial results for the quarter ended March 31, 2024.","evidence_excerpt":"On May 2, 2024, Kymera Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1815442/000095017024051566/0000950170-24-051566-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}